Associated Papers
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer.
Zapata Dongo RJ et al.
Frontiers in Pharmacology, 2025
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY et al.
Bmc Cancer, 2016
26782967 (PubMed )
Supplement: 12885_2016_2049_MOESM1_ESM.xlsx › Sheet1
Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants.
McDuff FK et al.
Molecular Carcinogenesis, 2013
Select a paper to view details